Outlook on the Oligonucleotide Synthesis Global Market to 2027 - by Product, Application, End-use and Region

News provided by

Dec 14, 2022, 10:00 ET

DUBLIN, Dec. 14, 2022 /PRNewswire/ -- The "Oligonucleotide Synthesis Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.

The global oligonucleotide synthesis market reached a value of US$ 2.4 Billion in 2021. Looking forward, the publisher expects the market to reach US$ 4.8 Billion by 2027, exhibiting a CAGR of 12.25% during 2021-2027.

Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.

Oligonucleotide synthesis is a chemical process wherein short fragments of nucleic acids are linked to each other for forming desired sequenced products. It can be customized by researchers according to the application and their requirements. It is used as primers and probes in recombinant DNA technologies to develop monoclonal antibodies.

It is also utilized in biological, medical, forensic, and clinical applications for gene expression, cloning, molecular diagnostics, and genetic disease screening. Moreover, it is gaining traction in therapeutics practices for several drugs on account of the introduction of automated reactor platforms, which provide access to oligonucleotides at reasonable prices.

With the increasing cases of coronavirus disease (COVID-19) and the urgency for a potential treatment, new generations of oligonucleotide drugs, including mRNA and DNA vaccines, are currently under development. Apart from this, the growing incidences of cancer and other chronic illnesses have resulted in the rising demand for novel diagnostics, which is influencing the need for oligonucleotide synthesis to help develop effective therapies and diagnostic techniques. The increasing geriatric population and demand for personalized medicines are also bolstering the market growth.

Additionally, with advances in purification and quality control technologies, the overall cost of oligonucleotide techniques can be decreased while substantially increasing quality and yield. This is promoting the application of oligonucleotide synthesis in a range of available modifications. Apart from this, several oligonucleotide-based therapies are in different stages of clinical trials. This is anticipated to propel the demand for oligonucleotide synthesis to treat viral infections, rare genetic disorders, and neuromuscular conditions.

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Agilent Technologies Inc., Biolegio B.V., Bio-Synthesis Inc, Eurofins Genomics, GenScript, Horizon Discovery Ltd, Integrated DNA Technologies Inc (Danaher Corporation), Kaneka Eurogentec S.A. (Kaneka Corporation), LGC Limited, Nitto Denko Avecia Inc (Nitto Denko Corporation) and Thermo Fisher Scientific Inc.

Key Questions Answered in This Report:

How has the global oligonucleotide synthesis market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global oligonucleotide synthesis market?
What are the key regional markets?
What is the breakup of the market based on the product?
What is the breakup of the market based on the application?
What is the breakup of the market based on the end use?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global oligonucleotide synthesis market and who are the key players?
What is the degree of competition in the industry?

Key Topics Covered:

1 Preface

2 Scope and Methodology

3 Executive Summary

4 Introduction
4.1 Overview
4.2 Key Industry Trends

5 Global Oligonucleotide Synthesis Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market Breakup by Product
6.1 Synthesized Oligonucleotide Products
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Reagents
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Equipment
6.3.1 Market Trends
6.3.2 Market Forecast
6.4 Services
6.4.1 Market Trends
6.4.2 Market Forecast

7 Market Breakup by Application
7.1 PCR Primers
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 PCR Assays and Panels
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Sequencing
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 DNA Microarrays
7.4.1 Market Trends
7.4.2 Market Forecast
7.5 Fluorescence In-Situ Hybridization (FISH)
7.5.1 Market Trends
7.5.2 Market Forecast
7.6 Antisense Oligonucleotides
7.6.1 Market Trends
7.6.2 Market Forecast
7.7 Others
7.7.1 Market Trends
7.7.2 Market Forecast

8 Market Breakup by End Use
8.1 Pharmaceutical and Biotechnology Companies
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Hospital and Diagnostic Laboratories
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Academic Research Institutes
8.3.1 Market Trends
8.3.2 Market Forecast

9 Market Breakup by Region

10 SWOT Analysis

11 Value Chain Analysis

12 Porters Five Forces Analysis

13 Price Analysis

14 Competitive Landscape
14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
14.3.1 Agilent Technologies Inc.
14.3.1.1 Company Overview
14.3.1.2 Product Portfolio
14.3.1.3 Financials
14.3.1.4 SWOT Analysis
14.3.2 Biolegio B.V.
14.3.2.1 Company Overview
14.3.2.2 Product Portfolio
14.3.3 Bio-Synthesis Inc
14.3.3.1 Company Overview
14.3.3.2 Product Portfolio
14.3.4 Eurofins Genomics
14.3.4.1 Company Overview
14.3.4.2 Product Portfolio
14.3.5 GenScript
14.3.5.1 Company Overview
14.3.5.2 Product Portfolio
14.3.6 Horizon Discovery Ltd
14.3.6.1 Company Overview
14.3.6.2 Product Portfolio
14.3.7 Integrated DNA Technologies Inc (Danaher Corporation)
14.3.7.1 Company Overview
14.3.7.2 Product Portfolio
14.3.8 Kaneka Eurogentec S.A. (Kaneka Corporation)
14.3.8.1 Company Overview
14.3.8.2 Product Portfolio
14.3.9 LGC Limited
14.3.9.1 Company Overview
14.3.9.2 Product Portfolio
14.3.10 Nitto Denko Avecia Inc (Nitto Denko Corporation)
14.3.10.1 Company Overview
14.3.10.2 Product Portfolio
14.3.11 Thermo Fisher Scientific Inc.
14.3.11.1 Company Overview
14.3.11.2 Product Portfolio
14.3.11.3 Financials
14.3.11.4 SWOT Analysis